

Technology Advisory Committee B Interests Register

Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Peter Wheatley Price	TAC B Member	Direct	Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505). They have just successfully exited the CDF (ID1635). We are also in process to evaluate usage in frontline.	08/02/2024	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
Veline L'Esperance	TAC B Member	Indirect - Financial	Employer received funding from GSK regarding shingles vaccination uptake. Veline is the PI on the project.	14/03/2024	It was agreed that Veline's declaration would not prevent her from participating in discussions on this appraisal.
Scott Purdon	Patient Expert	Indirect – Financial	We have received funding for a specific research project from the manufacturer of the technology in the last 12 months (£19,259). In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849).	14/03/2024	It was agreed that Scott's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Jon Missin	Patient expert	Indirect – Financial	We have received funding for a specific research project from the manufacturer of the technology in the last 12 months (£19,259). 2022. In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849).	14/03/2024	It was agreed that Jon's declaration would not prevent him from providing expert advice to the committee.
Gordon Cook	Clinical expert	Direct - Professional	Consultancy – BMS/Celgene, Takeda, Janssen, Sanofi, Roche, Amgen, Pfizer, Abbvie Indirect - Research Funding – BMS/Celgene, Takeda, Janssen	14/03/2024	It was agreed that Gordon's declaration would not prevent him from providing expert advice to the committee.